<DOC>
	<DOC>NCT01766518</DOC>
	<brief_summary>Efficacy and safety of MY-REPT capsule in primary, liver transplantation recipients</brief_summary>
	<brief_title>The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)</brief_title>
	<detailed_description>Open label, Multicenter, Non-comparative Study to evaluate the efficacy and safety of MY-REPT capsule in primary, liver transplantation</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient with primary liver transplantation recipients Male and Female aged ≥19 and ≤65 Patient with ABO blood type correspond with Donor's blood type Patient who agreement with written informed consent Patient who Women if had childbearing potential must have a negative serum or urine pregnancy test at the screening visit and agreement with contraception Patient with secondary liver transplantation(LT) recipient or other organ transplantation recipient in past or current Patient with multiorgan transplantation recipient Patient with dualgraft transplantation recipient Patient who used body artificial liver before LT Cr level &gt;2.0mg/dL in screening WBC &lt;2,000/mm3 or ANC &lt;900/mm3 or PLT &lt;30,000/mm3 in screening Patient who experienced severe gastrointestinal disorder so investigator judge the man's participation impossible Patient who experienced severe infection (need to treatment) Patient or Donor with HIV positive Patient who need to treat with immunosuppressant or chemistry therapy Patient who had taken immunosuppressant within 30days before LT (except to take Corticosteroids and Tacrolimus due to protocol)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>LT</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>MMF</keyword>
</DOC>